Tamoxifen, a selective estrogen receptor modulator (SERM), is used as an estrogen antagonist for all stages of breast cancer. Toremifene, a chlorinated derivative of tamoxifen, in a worldwide phase III trial demonstrated similar efficacy and safety for the treatment of advanced breast cancer (1). Tamoxifen’s clinical use is associated with a two to threefold increased risk of endometrial cancer. No conclusive clinical data regarding the effects of toremifene on endometrium are available today (1, 2). A case of a patient who undertook at first tamoxifen and then toremifene is reported.
Endometrial damage by antiestrogens in a postmenopausal breast cancer patient
BETTOCCHI, Stefano;
2002-01-01
Abstract
Tamoxifen, a selective estrogen receptor modulator (SERM), is used as an estrogen antagonist for all stages of breast cancer. Toremifene, a chlorinated derivative of tamoxifen, in a worldwide phase III trial demonstrated similar efficacy and safety for the treatment of advanced breast cancer (1). Tamoxifen’s clinical use is associated with a two to threefold increased risk of endometrial cancer. No conclusive clinical data regarding the effects of toremifene on endometrium are available today (1, 2). A case of a patient who undertook at first tamoxifen and then toremifene is reported.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
